205 related articles for article (PubMed ID: 14514923)
21. Significance of genetic abnormalities of p53 protein in Slovenian patients with gastric carcinoma.
Juvan R; Hudler P; Gazvoda B; Repse S; Bracko M; Komel R
Croat Med J; 2007 Apr; 48(2):207-17. PubMed ID: 17436385
[TBL] [Abstract][Full Text] [Related]
22. Loss of heterozygosity and microsatellite instability as predictive markers for neoadjuvant treatment in gastric carcinoma.
Grundei T; Vogelsang H; Ott K; Mueller J; Scholz M; Becker K; Fink U; Siewert JR; Höfler H; Keller G
Clin Cancer Res; 2000 Dec; 6(12):4782-8. PubMed ID: 11156235
[TBL] [Abstract][Full Text] [Related]
23. [Study on the p53 gene mutation and microsatellite instability of gastric carcinoma].
Guo W; Zhang Y; Wu B; Zhang L; Zhou D
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2000 Apr; 17(2):101-4. PubMed ID: 10751531
[TBL] [Abstract][Full Text] [Related]
24. Clinicopathologic features of gastric cancer with synchronous and metachronous colorectal cancer in Korea: are microsatellite instability and p53 overexpression useful markers for predicting colorectal cancer in gastric cancer patients?
Kim HJ; Kim N; Choi YJ; Yoon H; Shin CM; Park YS; Lee HS; Ahn SH; Park do J; Kim HH; Son IT; Kang SB; Lee DH
Gastric Cancer; 2016 Jul; 19(3):798-807. PubMed ID: 26445944
[TBL] [Abstract][Full Text] [Related]
25. Microsatellite instability in precancerous lesions and adenocarcinomas of the stomach.
Semba S; Yokozaki H; Yamamoto S; Yasui W; Tahara E
Cancer; 1996 Apr; 77(8 Suppl):1620-7. PubMed ID: 8608553
[TBL] [Abstract][Full Text] [Related]
26. P53 alteration and microsatellite instability have predictive value for survival benefit from chemotherapy in stage III colorectal carcinoma.
Elsaleh H; Powell B; McCaul K; Grieu F; Grant R; Joseph D; Iacopetta B
Clin Cancer Res; 2001 May; 7(5):1343-9. PubMed ID: 11350904
[TBL] [Abstract][Full Text] [Related]
27. Prognostic value of microsatellite instability and p53 expression in metastatic colorectal cancer treated with oxaliplatin and fluoropyrimidine-based chemotherapy.
Nöpel-Dünnebacke S; Schulmann K; Reinacher-Schick A; Porschen R; Schmiegel W; Tannapfel A; Graeven U
Z Gastroenterol; 2014 Dec; 52(12):1394-401. PubMed ID: 25474278
[TBL] [Abstract][Full Text] [Related]
28. Genetic and immunohistochemical analyses of p53 independently predict regional metastasis of gastric cancers.
Shiao YH; Palli D; Caporaso NE; Alvord WG; Amorosi A; Nesi G; Saieva C; Masala G; Fraumeni JF; Rice JM
Cancer Epidemiol Biomarkers Prev; 2000 Jun; 9(6):631-3. PubMed ID: 10868700
[TBL] [Abstract][Full Text] [Related]
29. Mdm2 gene amplification in gastric cancer correlation with expression of Mdm2 protein and p53 alterations.
Günther T; Schneider-Stock R; Häckel C; Kasper HU; Pross M; Hackelsberger A; Lippert H; Roessner A
Mod Pathol; 2000 Jun; 13(6):621-6. PubMed ID: 10874665
[TBL] [Abstract][Full Text] [Related]
30. Prognostic value of multidrug resistance 1, glutathione-S-transferase-pi and p53 in advanced nasopharyngeal carcinoma treated with systemic chemotherapy.
Hsu CH; Chen CL; Hong RL; Chen KL; Lin JF; Cheng AL
Oncology; 2002; 62(4):305-12. PubMed ID: 12138237
[TBL] [Abstract][Full Text] [Related]
31. Genetic changes in Slovenian patients with gastric adenocarcinoma evaluated in terms of microsatellite DNA.
Gazvoda B; Juvan R; Zupanic-Pajnic I; Repse S; Ferlan-Marolt K; Balazic J; Komel R
Eur J Gastroenterol Hepatol; 2007 Dec; 19(12):1082-9. PubMed ID: 17998833
[TBL] [Abstract][Full Text] [Related]
32. Analysis of genetic alterations associated with DNA diploidy, aneuploidy and multiploidy in gastric cancers.
Sugai T; Habano W; Jiao YF; Suzuki M; Takagane A; Nakamura S
Oncology; 2005; 68(4-6):548-57. PubMed ID: 16037688
[TBL] [Abstract][Full Text] [Related]
33. Expression of p53, p21 and p16 does not correlate with response to preoperative chemoradiation in gastric carcinoma.
Sirak I; Petera J; Hatlova J; Vosmik M; Melichar B; Dvorak J; Tycova V; Zoul Z; Lesko M
Hepatogastroenterology; 2009; 56(93):1213-8. PubMed ID: 19760973
[TBL] [Abstract][Full Text] [Related]
34. Loss of heterozygosity: an independent prognostic factor of colorectal cancer.
Chang SC; Lin JK; Lin TC; Liang WY
World J Gastroenterol; 2005 Feb; 11(6):778-84. PubMed ID: 15682467
[TBL] [Abstract][Full Text] [Related]
35. [Influence of neoadjuvant chemotherapy on microsatellite instability in gastric carcinoma].
Sun XW; Zhan YQ; Li W; Xu L; Li JT; Chen XJ; Zhang RH; Xu DZ
Ai Zheng; 2006 Dec; 25(12):1493-6. PubMed ID: 17166373
[TBL] [Abstract][Full Text] [Related]
36. P53 is the strongest predictor of survival in high-risk primary breast cancer patients undergoing high-dose chemotherapy with autologous blood stem cell support.
Hensel M; Schneeweiss A; Sinn HP; Egerer G; Solomayer E; Haas R; Bastert G; Ho AD
Int J Cancer; 2002 Jul; 100(3):290-6. PubMed ID: 12115543
[TBL] [Abstract][Full Text] [Related]
37. Molecular predictors of survival after adjuvant chemotherapy for colon cancer.
Watanabe T; Wu TT; Catalano PJ; Ueki T; Satriano R; Haller DG; Benson AB; Hamilton SR
N Engl J Med; 2001 Apr; 344(16):1196-206. PubMed ID: 11309634
[TBL] [Abstract][Full Text] [Related]
38. Evaluation of p53 protein as a prognostic factor for oral cancer surgery.
Cutilli T; Leocata P; Dolo V; Altobelli E
Br J Oral Maxillofac Surg; 2013 Dec; 51(8):922-7. PubMed ID: 23791033
[TBL] [Abstract][Full Text] [Related]
39. Tumour stage, node stage, p53 gene status, and bcl-2 protein expression as predictors of tumour response to platin-fluorouracil chemotherapy in patients with squamous-cell carcinoma of the head and neck.
Fouret P; Temam S; Charlotte F; Lacau-St-Guily J
Br J Cancer; 2002 Dec; 87(12):1390-5. PubMed ID: 12454767
[TBL] [Abstract][Full Text] [Related]
40. Expression of p53 protein and resistance to preoperative chemotherapy in locally advanced gastric carcinoma.
Cascinu S; Graziano F; Del Ferro E; Staccioli MP; Ligi M; Carnevali A; Muretto P; Catalano G
Cancer; 1998 Nov; 83(9):1917-22. PubMed ID: 9806649
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
